The Company:
With deep expertise in chemistry, Nuvalent is working to create selective medicines designed with the goal to address the needs of patients with cancer. Nuvalent is an exciting early-stage company, bringing together experienced scientists and industry veterans with a proven track record in drug discovery, oncology drug development, and company building.
The Role:
Reporting to the Vice President, Commercial, the Vice President, Sales will be instrumental in building and leading the U.S. sales organization as we prepare for the launch of zidesamtinib and neladalkib, potential best-in-class therapies for biomarker-directed NSCLC. Reporting to the Vice President, Commercial, this individual will develop and execute the U.S. sales strategy, recruit and manage a high-performing field sales team, and oversee the establishment of a robust Sales Training function. Cross-functional collaboration will be key to ensuring launch readiness and market success.
Responsibilities:
• Sales Strategy Development: Design and execute a comprehensive U.S. sales strategy, ensuring market readiness and alignment with Nuvalent’s commercial goals.
• Lead the development of sales processes and infrastructure including customer targeting, territory alignment, patient-identification efforts, and incentive compensation programs.
• Team Building & Leadership: Recruit, hire, and develop a high-performing field sales team capable of driving excellence in execution and customer engagement
• Serve as a member of the US Commercial leadership team, contributing to strategic direction and attainment of company-wide goals
• Sales Training Function: Establish and oversee a robust Sales Training program to prepare the field force with the skills and knowledge necessary to succeed in a dynamic market.
• Cross-Functional Collaboration: Partner closely with Marketing, Medical Affairs, Market Access, and other internal teams to ensure seamless launch readiness and market success.
o Work closely with the brand team to set launch targets, define key performance indicators (KPIs), and proactively manage incentives and metrics.
o Work closely with Legal, Regulatory, and Compliance to ensure all sales activities and are compliant with industry regulations and guidelines.
o Collaborate with the Market Access on account strategy that coordinates the efforts of the sales team and other field teams.
o Collaborate with Market Access to support patient access to our medicines. Continuously assess performance and adjust strategies to optimize results.
o Ensure coordination of field-facing teams working with Medical Affairs
• Launch Preparation: Lead sales readiness initiatives for the successful commercialization of zidesamtinib and neladalkib, aligning resources and strategies to maximize impact.
Competencies Include:
• Foster a culture of empowerment, collaboration, and a focus on patient impact.
• Strong scientific and clinical orientation, comfortable with data, and ability to distill complex clinical information into business implications and credible narrative with internal and external stakeholders.
• Exceptional communication and influence skills, with the ability to inspire confidence and work successfully with varied stakeholders including KOLs and organized customers.
• Drives for results- creates and nurture a performance-based culture of continuous improvement, addressing concerns and conflict proactively.
• Characteristics include being entrepreneurial, collaborative, and an energetic self-starter with strong interpersonal and analytical skills.
Qualifications:
• Bachelor’s degree. MBA or equivalent degree preferable
• 15+ years biopharma experience including oncology launch experience; NSCLC and biotech experience preferable
• 10+ years of US oncology sales experience in leadership roles
• Demonstrated organizational skills to manage multiple projects simultaneously, prioritize projects effectively and communicate at all levels within the company
• Strong knowledge of analytics and operations tools/technologies
• Strong written and verbal communication skills (including presentation skills)
• Up to 50% domestic travel
Nuvalent provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to religion, race, creed, color, sex, sexual orientation, alienage or citizenship status, national origin, age, marital status, pregnancy, disability, veteran or military status, predisposing genetic characteristics or any other characteristic protected by applicable federal, state or local law.
Nuvalent is aware that many companies are dealing with fraudulent job postings on third-party employment search sites and/or individual(s) or entities claiming to be employees of such companies. Those involved are offering fraudulent employment opportunities to applicants, often asking for sensitive personal and financial information, and using such information for criminal activities.
Please be advised that all legitimate correspondence from a Nuvalent employee will come from "@nuvalent.com" email accounts. Automated system response emails from our Greenhouse applicant tracking system come from a “no-reply@greenhouse.io” email address. There are no variations of these email addresses and Nuvalent would not request personal and/or financial information via email. Job opportunities would only be extended after a completed job application is submitted by a candidate and a thorough interview process including 1:1 and/or group interviews via phone, video conferencing and/or in-person.
If you believe you have been contacted by anyone misrepresenting themselves as an employee of Nuvalent, please contact Nuvalent at 857-357-7000. Thank you.
What We Do
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
